LSD molecule:

Image from PubChem

LSD Clinical Trials

A Single-Dose, Randomized, Double Blind, Placebo and Active Controlled Cross-Over Study to Evaluate the Abuse Potential of Three Doses of GRT0151Y in Adult Non-dependent Recreational Opiate Users

To see complete record on, please visit this link

Id: NCT03768024

Organisation Name: Grünenthal GmbH

Overal Status: Completed

Start Date: June 21, 2007

Last Update: December 7, 2018

Lead Sponsor: Grünenthal GmbH

Brief Summary: The purpose of this clinical study was to evaluate whether healthy adults, who sometimes take drugs for pleasure, are likely to abuse GRT0151Y. This abuse potential is assessed at three different doses of GRT0151Y.

During a Qualification Phase, a single dose of hydromorphone IR 8 mg and a single dose of placebo were separately administered orally over 4 days in a randomized, double-blinded manner.

During the Treatment Phase, single doses of GRT0151Y free base (100 mg, 200 mg and 400 mg), hydromorphone Immediate-release (IR) (4 mg, 8 mg, and 16 mg), and placebo were administered orally over 7 Treatment Periods.

Participants received the treatments according to a 7-sequence, 7-period balanced design.

  • Pain
  • Acute Pain

Total execution time in seconds: 0.3077700138092